Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 43 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

30%

13 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

14 recruiting

Enrollment Performance

Analytics

Phase 3
13(36.1%)
Phase 2
13(36.1%)
N/A
9(25.0%)
Early Phase 1
1(2.8%)
36Total
Phase 3(13)
Phase 2(13)
N/A(9)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (43)

Showing 20 of 43 trials
NCT07575321Not ApplicableNot Yet Recruiting

Intrathecal Morphine for Quality of Recovery After Open Abdominal Surgery Within an Enhanced Recovery Pathway

Role: collaborator

NCT07311772Phase 3Recruiting

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Role: collaborator

NCT07095023Not ApplicableRecruiting

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

Role: collaborator

NCT06737913Phase 2Recruiting

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT07388758Phase 2Not Yet Recruiting

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT07188584Phase 3Recruiting

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

Role: collaborator

NCT04695925Phase 3Active Not Recruiting

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Role: collaborator

NCT04669496Phase 2Active Not Recruiting

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Role: collaborator

NCT06288360Phase 2Recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Role: collaborator

NCT05464875Recruiting

A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors

Role: collaborator

NCT05440357Recruiting

Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study

Role: collaborator

NCT05461664Recruiting

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

Role: collaborator

NCT06709144Phase 3Active Not Recruiting

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

Role: collaborator

NCT05512286Not ApplicableRecruiting

Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction

Role: collaborator

NCT06288373Phase 2Recruiting

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Role: collaborator

NCT06035250Recruiting

AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Role: collaborator

NCT05023109Phase 2Unknown

GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Role: collaborator

NCT02288195Phase 3Unknown

CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients

Role: collaborator

NCT05707819Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Role: lead

NCT05131698Early Phase 1Unknown

Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma

Role: lead